HLP005, or HLP-005, also known as deuterated phenethylamine derivative and formerly as CYB005, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of psychiatric disorders and neuroinflammation.
HLP005 acts as a serotonin receptor agonist and is a serotonergic psychedelic. In addition, HLP005 may also inhibit serotonin and dopamine reuptake.
HLP005 is a phenethylamine derivative and a deuterated compound. The exact chemical structure of HLP005 does not yet seem to have been disclosed. However, it appears to be closely related to CYB210010 (CYB2108; 2C-T-36 or 2C-T-TFM), which itself is non-deuterated. In addition, HLP005's developer has patent protection for the compound, indicating that its chemical structure has been published in the patent literature. Some notable phenethylamines patented by Helus Pharma include the non-deuterated CYB2108 (2C-T-36) and its deuterated form CYB2108D (fully deuterated methoxy groups at 2 and 5 positions).
As of October 2024, HLP005 is in the research or preclinical stage of development. It has been in this developmental stage since at least 2022. The drug is under development by Helus Pharma (formerly Cybin). Other related drugs include the deuterated tryptamines CYB003 and CYB004.